OPKO Health (NASDAQ:OPK) Given Buy Rating at HC Wainwright

OPKO Health (NASDAQ:OPK)‘s stock had its “buy” rating reissued by analysts at HC Wainwright in a research report issued to clients and investors on Wednesday,Benzinga reports. They presently have a $3.00 price target on the biotechnology company’s stock. HC Wainwright’s target price would suggest a potential upside of 67.60% from the company’s current price. HC Wainwright also issued estimates for OPKO Health’s Q2 2025 earnings at ($0.07) EPS and FY2025 earnings at ($0.30) EPS.

Other research analysts have also recently issued reports about the stock. StockNews.com upgraded shares of OPKO Health from a “sell” rating to a “hold” rating in a report on Monday, March 3rd. Barrington Research reissued an “outperform” rating and issued a $2.25 price target on shares of OPKO Health in a research report on Wednesday, March 12th.

OPKO Health Price Performance

Shares of NASDAQ OPK opened at $1.79 on Wednesday. OPKO Health has a twelve month low of $0.86 and a twelve month high of $2.04. The firm has a fifty day simple moving average of $1.63 and a 200 day simple moving average of $1.57. The company has a market capitalization of $1.20 billion, a PE ratio of -9.42 and a beta of 1.70. The company has a quick ratio of 2.69, a current ratio of 2.97 and a debt-to-equity ratio of 0.30.

OPKO Health (NASDAQ:OPK) last posted its quarterly earnings results on Thursday, February 27th. The biotechnology company reported $0.01 earnings per share for the quarter, beating the consensus estimate of ($0.08) by $0.09. The firm had revenue of $183.60 million during the quarter, compared to the consensus estimate of $155.42 million. OPKO Health had a negative net margin of 18.65% and a negative return on equity of 9.76%. On average, sell-side analysts forecast that OPKO Health will post -0.25 EPS for the current year.

Insiders Place Their Bets

In related news, CEO Phillip Md Et Al Frost purchased 150,000 shares of the company’s stock in a transaction dated Friday, January 17th. The shares were purchased at an average price of $1.47 per share, with a total value of $220,500.00. Following the acquisition, the chief executive officer now directly owns 213,186,477 shares in the company, valued at $313,384,121.19. The trade was a 0.07 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In the last ninety days, insiders purchased 964,971 shares of company stock worth $1,493,692. 47.26% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On OPKO Health

Institutional investors and hedge funds have recently made changes to their positions in the business. FMR LLC boosted its holdings in shares of OPKO Health by 103.6% in the third quarter. FMR LLC now owns 21,795 shares of the biotechnology company’s stock worth $32,000 after buying an additional 11,089 shares during the last quarter. Wealth Enhancement Advisory Services LLC raised its stake in OPKO Health by 75.3% during the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 28,908 shares of the biotechnology company’s stock worth $42,000 after acquiring an additional 12,417 shares during the period. Orion Portfolio Solutions LLC bought a new stake in OPKO Health during the 3rd quarter worth approximately $45,000. Cibc World Markets Corp bought a new stake in OPKO Health during the 4th quarter worth approximately $45,000. Finally, Zacks Investment Management bought a new stake in shares of OPKO Health during the fourth quarter valued at approximately $49,000. Hedge funds and other institutional investors own 64.63% of the company’s stock.

About OPKO Health

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.